Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first-line treatment for Chinese population with unresectable hepatocellular carcinoma in Taiwan
- At: Seville (Spain) (2022)
- Type: Poster
- Poster code: SAP-057
- By: TSENG, Chien-Yu (National Yang Ming Chiao Tung University, Taiwan China)
- Co-author(s): Ms Chien-Yu Tseng, Pharmacy (National Yang Ming Chiao Tung University, Taipei, Taiwan China)
Dr. Ming-Neng Shiu, Pharmacy (National Yang Ming Chiao Tung University, Taipei, Taiwan China)
Introduction: The IMbrave150 trial showed that the combined treatment of atezolizumab and bevacizumab (A+B) significantly prolonged the overall survival and progression-free survival in unresectable hepatocellular carcinoma (HCC) patients. Moreover, the A+B treatment had higher efficacy in the Chinese subpopulation when compared to the overall.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.